CTNI-27. FIRST-IN-PEDIATRICS PHASE I STUDY OF GDC-0084 (PAXALISIB), A CNS-PENETRANT PI3K/mTOR INHIBITOR, IN NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) OR OTHER DIFFUSE MIDLINE GLIOMA (DMG)

BACKGROUND: GDC-0084 is an oral, highly selective and potent inhibitor of class I PI3K and moderate inhibitor of mTOR, with an established adult maximum tolerated dose (MTD) of 60 mg/day and evidence of brain tumor penetration in adult recurrent glioblastoma. METHODS: We used a rolling-6 design to e...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Tinkle, Christopher, Huang, Jie, Campagne, Olivia, Pan, Haitao, Onar-Thomas, Arzu, Chiang, Jason, Klimo, Paul, Boop, Rick, Patay, Zoltan, Shulkin, Barry, Lucas, John, Merchant, Thomas, Upadhyaya, Santhosh, Robinson, Giles, Vinitsky, Anna, Stewart, Clinton, Gajjar, Amar
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Clinical Trials: Non-Immunologic
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650438/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.194
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados